Myriad myChoice CDx is the industry’s most clinically-validated genomic instability test. The test enables physicians to identify patients with tumors that have lost the ability to repair double ...

SALT LAKE CITY, Oct. 08, 2016 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (MYGN), a leader in molecular diagnostics and personalized medicine, today announced that its myChoice ® HRD test ...

Leading player in the molecular diagnostics and personalized medicine space, Myriad Genetics Inc.MYGN, announced that its myChoice homologous recombination deficiencies (HRD) test will effectively ...

The filing comes as recent upgrades to NCCN guidelines expand the role of testing in the treatment of ovarian cancer. Myriad Genetics this week submitted the first part of its application to the ...

With this alliance, Myriad's MyChoice HRD Plus and MyChoice CDx Plus Tests, collectively known as Myriad's MyChoice Tests, are now part of a new sponsored testing program that is accessible in ...

About myChoice ® HRD Myriad's myChoice HRD is the most comprehensive homologous recombination deficiency test, enabling physicians to identify tumors that have lost the ability to repair double ...

Myriad Genetics Receives Additional Reimbursement for myChoice® Diagnostic System in Japan Comprehensive Test Helps Identify Women with Advanced Ovarian Cancer Who May Benefit from First-Line ...

The test that is most often used for the detection of HRD in clinical studies is the Myriad myChoice assay. However, other assays can also be used to assess biomarkers, which are indicative of HRD, ...

Myriad myChoice CDx is the industry’s most clinically-validated genomic instability test. The test enables physicians to identify patients with tumors that have lost the ability to repair double ...

SALT LAKE CITY, Oct. 08, 2016 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (MYGN), a leader in molecular diagnostics and personalized medicine, today announced that its myChoice ® HRD test identified ...